Skip to main content
SpringerLink
Log in

Restoration of hypothalamic signaling systems as a cause of improved metabolic parameters in rats with neonatal diabetes model during treatment with bromocriptine mesylate

  • Published:
Cell and Tissue Biology Aims and scope Submit manuscript

Abstract

One approach to correction of diabetes mellitus 2 type (DM2) and its complications is the use of bromocriptine mesylate (BCM), a selective agonist of the dopamine receptor type 2 (DA2R). However, the effectiveness and mechanisms of the action of BCM in the treatment of severe forms of DM2 forms currently not understood. The purpose of this study was to investigate the influence of 4-week treatment of male rats with neonatal DM2 model using BCM (300 mg/kg daily) on their metabolic parameters and on the activity of the adenylyl cyclase signaling system (ACSS) in the hypothalamus. Exposure to BCM restored glucose tolerance and glucose utilization by exogenous insulin, normalized lipid metabolism, and lowered triglycerides and atherogenic cholesterol levels, which are elevated in DM2. In the hypothalamus of diabetic rats treated with BCM, the regulation of ACSS by agonists of melanocortin receptors type 4 (MC4R), DA2R, and serotonin 1B-subtype receptors and expression of the Mc4r gene encoding MC4R were restored. Furthermore, BCM treatment did not influence the insulin levels in the blood and its production by pancreatic β-cells. The data indicate that the use of BCM to correct severe forms of experimental DM2 holds promise and show that the therapeutic potential of this drug is based on its ability to restore signaling systems of the hypothalamus that are sensitive to monoamines and peptides of the melanocortin family, which are responsible for the control of energy metabolism and insulin sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AC:

adenylyl cyclase

ACSS:

adenylyl cyclase signaling system

BCM:

bromocriptine mesylate

GTT:

glucose-tolerance test

DA1R and DA2R:

dopamine receptors 1 and 2 types, respectively

IGTT:

insulin glucose-tolerance test

MC4R:

melanocortin receptor 4-type

α-MSH:

α-melanocyte stimulating hormone

5-NOT:

5-nonyloxytryptamine

DM2:

diabetes mellitus type 2

HT1ВR:

serotonin receptor 1B-subtype

TG:

triglycerides

HDL-C and LDL-C:

a complex of cholesterol with lipoproteins of high and low density, respectively

References

  • Beaulieu, J.M., Gainetdinov, R.R., and Caron, M.G., The Akt-GSK-3 signaling cascade in the actions of dopamine, Trends Pharmacol. Sci., 2007, vol. 28, pp. 166–172.

    Article  CAS  PubMed  Google Scholar 

  • Chamarthi, B., Gaziano, J.M., Blonde, L., Vinik, A., Scranton, R.E., Ezrokhi, M., Rutty, D., and Cincotta, A.H., Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus, J. Diabet. Res., 2015, vol. 2015, p. 157698.

    Article  Google Scholar 

  • Derkach, K.V., Bondareva, V.M., Moiseyuk, I.V., and Shpakov, A.O., The effect of 2-month bromocriptine treatment on the activity of the adenylate cyclase signaling system in the myocardium and testes of rats with type 2 diabetes, Cell Tissue Biol., 2014, vol. 9, no. 5, pp. 395–405.

    Article  Google Scholar 

  • Derkach, K.V., Bondareva, V.M., Chistyakova, O.V., Berstein, L.M., and Shpakov, A.O., The effect of long-term intranasal serotonin treatment on metabolic parameters and hormonal signaling in rats with high-fat diet/low-dose streptozotocin-induced type 2 diabetes, Int. J. Endocrinol., 2015, vol. 2015, pp. 245459.

    Article  PubMed  PubMed Central  Google Scholar 

  • Deuschle, M., Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults, Curr. Opin. Psychiatry, 2013, vol. 26, pp. 60–65.

    Article  PubMed  Google Scholar 

  • Fan, W., Dinulescu, D.M., Butler, A.A., Zhou, J., Marks, D.L., and Cone, R.D., The central melanocortin system can directly regulate serum insulin levels, Endocrinology, 2000, vol. 141, pp. 3072–3079.

    Article  CAS  PubMed  Google Scholar 

  • Farooqi, I.S., Keogh, J.M., Yeo, G.S., Lank, E.J., Cheetham, T., and O’Rahilly, S., Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene, New Engl. J. Med., 2003, vol. 348, pp. 1085–1095.

    Article  CAS  PubMed  Google Scholar 

  • Gaziano, J.M., Cincotta, A.H., Vinik, A., Blonde, L., Bohannon, N., and Scranton, R., Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects, J. Amer. Heart Assoc., 2012, vol. 1, p. E002279.

    Article  Google Scholar 

  • Grunberger, G., Novel therapies for the management of type 2 diabetes mellitus: part 1, pramlintide and bromocriptine-QR, J. Diabetes, 2013, vol. 5, pp. 110–117.

    Article  CAS  PubMed  Google Scholar 

  • Kerr, J.L., Timpe, E.M., and Petkewicz, K.A., Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus, Ann. Pharmacother., 2010, vol. 44, pp. 1777–1785.

    Article  CAS  PubMed  Google Scholar 

  • Luo, S., Luo, J., and Cincotta, A.H., Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hmster, Chronobiol. Int., 2000, vol. 17, pp. 155–172.

    Article  PubMed  Google Scholar 

  • Lustman, P.J. and Clouse, R.E., Depression in diabetic patients: the relationship between mood and glycemic control, J. Diabetes Complicat., 2005, vol. 19, pp. 113–122.

    PubMed  Google Scholar 

  • Mebel, D.M., Wong, J.C., Dong, Y.J., and Borgland, S.L., Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake, Eur. J. Neurosci., 2012, vol. 36, pp. 2336–2346.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mikhail, N., Quick-release bromocriptine for treatment of type 2 diabetes, Curr. Drug Deliv., 2011, vol. 8, pp. 511–516.

    Article  CAS  PubMed  Google Scholar 

  • Morgan, D.A., McDaniel, L.N., Yin, T., Khan, M., Jiang, J., Acevedo, M.R., Walsh, S.A., Ponto, L.L., Norris, A.W., Lutter, M., Rahmouni, K., and Cui, H., Regulation of glucose tolerance and sympathetic activity by MC4R signaling in the lateral hypothalamus, Diabetes, 2015, vol. 64, pp. 1976–1987.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nade, V.S., Kawale, L.A., Todmal, U.B., and Tajanpure, A.B., Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats, Indian J. Pharmacol., 2012, vol. 44, pp. 688–693.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nogueiras, R., Wiedmer, P., Perez-Tilve, D., Veyrat-Durebex, C., Keogh, J.M., Sutton, G.M., Pfluger, P.T., Castaneda, T.R., Neschen, S., Hofmann, S.M., Howles, P.N., Morgan, D.A., Benoit, S.C., Szanto, I., Schrott, B., Schürmann, A., Joost, H.G., Hammond, C., Hui, D.Y., Woods, S.C., Rahmouni, K., Butler, A.A., Farooqi, I.S., O’Rahilly, S., Rohner-Jeanrenaud, F., and Tschöp, M.H., The central melanocortin system directly controls peripheral lipid metabolism, J. Clin. Invest., 2007, vol. 117, pp. 3475–3488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pandit, R., de, Jong, J.W., Vanderschuren, L.J., and Adan, R.A., Neurobiology of overeating and obesity: the role of melanocortins and beyond, Eur. J. Pharmacol., 2011, vol. 660, pp. 28–42.

    Article  CAS  PubMed  Google Scholar 

  • Pijl, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V., Pipek, R., Iozzo, P., Lancaster, J.L., Cincotta, A.H., and DeFronzo, R.A., Bromocriptine: a novel approach to the treatment of type 2 diabetes, Diabetes Care, 2000, vol. 23, pp. 1154–1161.

    Article  CAS  PubMed  Google Scholar 

  • Ryan, G., Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors, Postgrad. Med., 2015, vol. 127, pp. 842–854.

    Article  PubMed  Google Scholar 

  • Scranton, R. and Cincotta, A., Bromocriptine—unique formulation of a dopamine agonist for the treatment of type 2 diabetes, Expert. Opin. Pharmacother., 2010, vol. 11, pp. 269–279.

    Article  CAS  PubMed  Google Scholar 

  • Shpakov, A.O. and Derkach, K.V., The functional state of hormone-sensitive adenylyl cyclase signaling system in diabetes mellitus, J. Signal Transduct., 2013, vol. 2013, p. 594213.

    Article  PubMed  PubMed Central  Google Scholar 

  • Shpakov, A.O. and Derkach, K.V., Gormonal’nye sistemy mozga i sakharny diabet 2-go tipa (The Brain Hormonal Signaling Systems and Type 2 Diabetes Mellitus), St. Petersburg: Izd. Politekh. Univ., 2015. ISBN 978-5-7422-4955-9.

    Google Scholar 

  • Shpakov, A.O., Chistyakova, O.V., Derkach, K.V., Moiseyuk, I.V., and Bondareva, V.M., Intranasal insulin affects adenylyl cyclase system in rat tissues in neonatal diabetes, Central Eur. J. Biol., 2012, vol. 7, pp. 33–47.

    CAS  Google Scholar 

  • Shpakov, A.O., Derkach, K.V., Chistyakova, O.V., and Bondareva, V.M., The influence of bromocryptine treatment on activity of the adenylyl cyclase system in the brain of rats with type 2 diabetes mellitus induced by high-fat diet, Dokl. Biochem. Biophys., 2014, vol. 459, no. 1, pp. 186–189.

    Article  CAS  PubMed  Google Scholar 

  • Sukhov, I.B., Derkach, K.V., Chistyakova, O.V., Bondareva, V.M., and Shpakov, A.O., The effect of prolonged intranasal administration of serotonin on the activity of hypothalamic signaling systems in male rats with neonatal diabetes, Cell Tissue Biol., 2016, vol. 10, no. 4, pp. 314–323.

    Article  Google Scholar 

  • Tao, Y.X., Mutations in melanocortin-4 receptor and human obesity, Prog. Mol. Biol. Transl. Sci., 2009, vol. 88, pp. 173–204.

    Article  CAS  PubMed  Google Scholar 

  • Vinik, A.I., Cincotta, A.H., Scranton, R.E., Bohannon, N., Ezrokhi, M., and Gaziano, J.M., Effect of bromocriptine-qr on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents, Endocr. Pract., 2012, vol. 18, pp. 931–943.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, 194223, Russia

    K. V. Derkach, A. O. Ivantsov, I. B. Sukhov & A. O. Shpakov

  2. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, 197758, Russia

    A. O. Ivantsov

Authors
  1. K. V. Derkach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. O. Ivantsov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. B. Sukhov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. O. Shpakov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. O. Shpakov.

Additional information

Original Russian Text © K.V. Derkach, A.O. Ivantsov, I.B. Sukhov, A.O. Shpakov, 2017, published in Tsitologiya, 2017, Vol. 59, No. 2, pp. 140–147.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Derkach, K.V., Ivantsov, A.O., Sukhov, I.B. et al. Restoration of hypothalamic signaling systems as a cause of improved metabolic parameters in rats with neonatal diabetes model during treatment with bromocriptine mesylate. Cell Tiss. Biol. 11, 234–241 (2017). https://doi.org/10.1134/S1990519X17030038

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1990519X17030038

Keywords

Search

Navigation